Genyous Biomed

News

November 16, 2007

Larry Goldenberg Appointed Chief Medical Officer-Urology

Genyous Biomed International (Genyous) announced the appointment of Dr. Larry Goldenberg as Chief Medical Officer-Urology. In this role, Dr. Goldenberg plays a leadership role in shaping Genyous' translational and clinical research plans for the management of prostate disorders such as prostate cancer.

Dr. Goldenberg currently serves as Professor and Chairman of the Department of Urologic Sciences at UBC, Director of Clinical Research at the Prostate Centre at Vancouver General Hospital, and a Fellow of the Canadian Academy of Health sciences. He is a co-founder of the Canadian Urologic-Oncology Group, and past-president of both the Canadian Urological Association and the Western section of the American Urological Association.

Through his vision and leadership, the Prostate Centre at Vancouver General Hospital has developed into one of the top prostate research, education and healthcare delivery programs in the world.

Dr. Larry Goldenberg was a pioneer in the use of intermittent hormone withdrawal for the management of prostate cancer, which is now used worldwide as a treatment option for this disease. His book, Prostate Cancer - All You Need to Know to Take an Active Part in Your Treatment, is considered one of the best reference sources for men with prostate disease in North America.

"We are very pleased by Dr. Goldenberg's decision to join our team," said Jim Dao, Chairman and CEO of Genyous. "With his clinical perspective, expertise, and leadership we hope to further refine our translational and clinical development plans to maximize the benefit of our MFMT solutions to reduce mortality and suffering due to prostate disorders."

November 14, 2007

Genyous Biomed International Announces New Member of Board of Directors

Genyous Biomed International (Genyous) announced today that Mr. David Korbin has become a member of its Board of Directors. Mr. Korbin will also serve on Genyous' audit committee.

Mr. David Korbin presently works as a management and financial consultant. He is also a director of E-Comm Emergency Communications for Southwest British Columbia. He has been Chairman of E-Comm's board of directors since 2004 and was Chairman of the audit committee from 2002 to 2003. From 1992 to 2000, he was a director of the Vancouver General Hospital and then the Vancouver Hospital and Health Sciences Centre, serving as Chairman of the Vancouver General Hospital audit committee from 1993 to 1994 and Chairman of the Vancouver Hospital and Health Sciences Centre from 1995 to 1998. Mr. Korbin qualified as a Chartered Accountant in 1966, and from 1990 to 1992 he was a managing partner of Deloitte Touche LLC. Mr. Korbin also is a director of Ivanhoe Mines (NASDAQ: IVN) and Seaspan Corporation (NYSE: SSW), and is Chairman of Seaspan's audit committee.

"We are very pleased that Mr. Korbin has accepted our invitation to join our Board. The addition of Mr. Korbin to Genyous' Board adds breadth as well as depth in terms of operational experience and knowledge of governance and compliance matters especially important to publicly listed companies," said James Dao, Chairman and CEO of Genyous.

October 10, 2006

Genyous Biomed International Receives Regulatory Approval for Aneustat™ (OMN54) Phase I Clinical Trial

Genyous Biomed International (Genyous) announced today that it has received regulatory approval to conduct a Phase I clinical trial of the Company's lead cancer therapy, Aneustat™ (OMN54).

Aneustat (OMN54) represents a new class of therapies designed to address the heterogeneous nature of cancer. Genyous' Multifunctional Multitargeted (MFMT™) therapies are formulated to provide multiple therapeutic effects in parallel in a manner that is both safe and efficacious.

Pre-clinical in vitro and in vivo studies of Aneustat (OMN54) suggest that:

  • Aneustat™ can be delivered orally and is well-tolerated (no harmful side effects at therapeutic doses)
  • Aneustat™ inhibits tumor growth (human tumor tissue xenografts in mice) of some lung and prostate cancers on par with standard combination chemotherapy regimens
  • Aneustat™ inhibits cancer through multiple genomic targets to induce apoptosis and impede metastasis
  • Aneustat™ has strong cancer inhibition synergy with leading chemotherapies, potentially enhancing efficacy and/or lowering toxicity
  • Aneustat™ regulates the cancer cell cycle in a manner that suggests that Aneustat may serve as an enhancer to increase efficacy of chemo or radiation therapy
  • Aneustat™ can be used as an adjuvant therapy or combination pharmaceutical

The Phase I clinical study is planned to take place at the BC Cancer Agency in Vancouver, British Columbia.

"The approval of our phase I clinical trial application by Health Canada is a major milestone for us. We are grateful for their cooperation and diligence in providing a swift review of our clinical trial application," said James Dao, Chairman & CEO of Genyous. "The decision to conduct the first clinical trial of Aneustat (OMN54) at the BC Cancer Agency was a natural choice given the long history of collaboration between Genyous and the BC Cancer Agency. Most of the pivotal efficacy and safety studies of Aneustat (OMN54) took place at the BC Cancer Agency. We are honored that Dr. Karen Gelmon has agreed to serve as the principal investigator in this study. Her expertise in Phase I oncology studies is extremely valuable."

About Genyous Biomed International_Genyous Biomed International was founded in 2000 with a mission to reduce mortality due to chronic diseases such as cancer. Genyous' proprietary Multifunctional Multitargeted (MFMT™) therapies are particularly well-suited to address the heterogeneous nature of cancer by delivering multiple therapeutic effects in parallel. More information can be found at http://www.genyous.com.

Aneustat and MFMT are trademarks of Genyous Biomed International, Inc.

February 10, 2006

Jerry Norskog Appointed President & COO of Vitala Therapeutics

Vitala Therapeutics, a marketing affiliate of Genyous Biomed International, announced the appointment of Mr. Jerry Norskog as the President and COO of Vitala Therapeutics. As Vitala's President and COO, Mr. Norksog will lead the implementation of the Company's strategy to launch its line of well-tolerated Multifunctional Multitargeted (MFMT™) therapies for supportive care and the reduction of risk of chronic diseases.

Mr. Norskog has served as an active member of the Board of Directors of Vitala since 2005 and he has over thirty years of experience in the pharmaceutical industry. Mr. Norskog held numerous senior management positions for various divisions of Johnson & Johnson in North America and throughout Asia Pacific. Mr. Norskog's most recent engagement was as President of McNeil Consumer Healthcare, the division of Johnson & Johnson that markets Tylenol.

"As a member of Genyous' Board, Jerry's vast commercial experience has been invaluable to help us refine our strategy. Now serving as an executive of Vitala, Jerry will help to realize the goal of reducing suffering due to chronic diseases," said James Dao, Chairman and CEO of Genyous, and CEO of Vitala.

January 1, 2006

Genyous Biomed International Announces New Members of Board of Directors

Genyous Biomed International (Genyous) announced today that Dr. Dave Alberts and Dr. John Ostrem have become members of its Board of Directors.

Dr. Alberts also serves as Genyous' Chief Clinical Science Officer and has been a member of the Company's oncology advisory panel since 2004.

Dr. John Ostrem has more than 30 years experience inventing new technology and bringing products to market. In 1982, he co-founded Communication Intelligence Corporation, a company specializing in natural input and electronic signature solutions where he served for 15 years as CTO and Senior VP of Research and Engineering. Subsequently Dr. Ostrem was Vice-President of R&D and Engineering at Dejima, a company that created and deployed user-friendly natural language interfaces. In 2001 Dr. Ostrem co-founded China MobileSoft, a company that developed telecommunications software for the Chinese and International markets, and at various times served as Chairman, CEO, and CTO. China MobileSoft's software was integrated into over 80 products. Dr. Ostrem oversaw the acquisition of China MobileSoft by PalmSource (the maker of the software used in the market leading Palm PDAs and smart phones). Dr. Ostrem began his career as a scientist and researcher at SRI (the former Stanford Research Institute). Dr. Ostrem has many scientific publications, patents, and has received numerous grants and awards from the National Science Foundation and NIST. As a member of the Genyous Board of Directors, Dr. Ostrem provides guidance on the medical application of nanotechnology and strategy regarding translational research and funding.

"We are honored to have Dr. Alberts and Dr. Ostrem join the Genyous Board of Directors. Their expertise in medicine, research and development, and commercialization brings valuable perspective," said James Dao, Chairman and CEO of Genyous.

October 11, 2005

Dave Alberts Appointed Chief Clinical Science Officer

Genyous Biomed International (Genyous) announced the appointment of Dr. David Alberts as Chief Clinical Science Officer. In this role, Dr. Alberts plays a leadership role in shaping Genyous' clinical research in cancer detection, prevention and treatment. Dr. Alberts increased his participation after having served on Genyous' oncology advisory panel since 1994.

Dr. David Alberts currently also serves as director of the Arizona Cancer Center at the University of Arizona and is a recognized leader in research in the prevention of cancer. He is a Regents Professor of Medicine, Pharmacology, Nutritional Sciences, Public Health, and BIO5 Institute, the University of Arizona, Tucson, Arizona. Dr. Alberts has been funded by the National Cancer Institute (NCI) yearly since 1971 for laboratory and clinical research related to the clinical pharmacology of cancer chemotherapy and chemopreventive agents, as well as the development of research strategies for the prevention of breast, cervix, colon, prostate and skin cancers.

Dr. Alberts has authored or co-authored more than 400 peer-reviewed publications, has served as editor and co-editor of four books and has served on several editorial boards.

"We are honored by Dr. Albert's growing interest and commitment to Genyous. His expertise brings invaluable perspective as we establish our priorities and develop our strategies to achieve our objectives in terms of bringing our products to patients," said Jim Dao, Chairman and CEO of Genyous.

September 22, 2005

Genyous Biomed Appoints Jeffrey Dao President & COO

Genyous Biomed International (Genyous) announced the promotion of Jeffrey Dao to President & COO. Mr. Dao joined Genyous in 2002 as senior vice president business development where he managed Genyous' product and corporate development programs. His initial focus was on Genyous' diagnostics efforts that spun off in 2004 as Perceptronix Medical Inc (PMI). Since 2004, Mr. Dao has contributed to Genyous' pharmaceutical development efforts. As President and COO of Genyous, Mr. Dao now oversees key aspects of the company's operations including product development, regulatory affairs, organization development, strategic alliance formation, product management and marketing.

Mr. Dao has twenty years of experience in the creation and management of emerging technology and new business development. Mr. Dao began his career as an application engineer at CIC, a leading developer of pattern recognition technologies. Over a period of 10 years, Mr. Dao became CIC's head of marketing and sales and contributed to the company's successful IPO on Nasdaq. Mr. Dao also served as Senior Director of Business Development for Oracle Corporation where he helped to build strategic alliances to support the company's CRM and e-Business objectives. Mr. Dao also served as Vice President of Business Development at Nokia Inc., where he managed acquisitions and built strategic alliances to support the company's Internet-communications objectives.

"Through 2005 Jeff effectively and efficiently managed the Company's product and corporate development programs and we look forward to his continued contribution in his new role," said James Dao, Chairman and CEO of Genyous.

May 25, 2005

Genyous Biomed Spins Out Vitala Therapeutics

Genyous Biomed International (Genyous) announced today that it has spun out its marketing subsidiary Vitala Therapeutics Inc. (Vitala). Vitala's mission is to commercialize therapies for supportive care and the prevention of chronic diseases. It is envisioned that Vitala will manage the commercialization of Genyous' lead MFMT supportive care and cancer risk reduction product, Thriva™ Prostate (VTT-201).

"This represents another important step in the realization of the Genyous strategy to market its MFMT therapies via focused commercialization entities. Like heart disease, we believe the key to ultimately reducing cancer mortality is via prevention. Using the latest scientific understanding of prostate carcinogenesis, we are formulating Thriva Prostate to support healthy prostate function which may also help to reduce risk of prostate cancer. This will be a powerful product for Vitala to enter the market with," said James Dao, Chairman, President, and CEO of Genyous.

Mr. Dao currently serves as the CEO of Vitala and will work to develop its management team.

October 2, 2004

Genyous Biomed Spins Out Omnitura Therapeutics To Commercialize Oncology Therapy Solutions

Genyous Biomed International (Genyous) announced today that it has spun out its marketing subsidiary Omnitura Therapeutics Inc. (Omnitura). Omnitura's mission is to commercialize Genyous' novel well-tolerated Multifunctional Multitargeted (MFMT™) cancer therapies. It is envisioned that Omnitura will manage the commercialization of Genyous' lead MFMT cancer therapy, Aneustat™ (OMN54). Pre-clinical efficacy and safety tests of Aneustat (OMN54) conducted in partnership with the BC Cancer Agency suggest that Aneustat may help to improve the standard of care for many high volume solid tumors such as lung and prostate cancer.

"This represents a key step in Genyous' strategy to market its growing pipeline of novel MFMT therapies via focused commercialization entities. Cancer continues to represent a large unmet clinical need and we have every reason to believe that our MFMT therapies can make a significant contribution in reducing suffering due to cancer," said James Dao, Chairman, President, and CEO of Genyous.

Mr. Dao currently serves as the CEO of Omnitura and will work to develop its management team.

August 2, 2004

Genyous Biomed International Announces New Members of Board of Directors

Genyous Biomed International (Genyous) announced today the appointment of Mr. Herbert Lechner and Mr. Jerry Norksog to its Board of Directors.

Mr. Lechner has extensive experience in the development and management of technology. Mr. Lechner started his career at IBM, where he eventually became Director of IBM's US Navy & Air Force Systems business. As corporate officer of companies such as the Singer Company and American Express, Mr. Lechner implemented strategic and operational goals through the use of information technology. Mr. Lechner headed systems administration at SRI International (formerly Stanford Research Institute) where he directed various applied research programs that involved over 400 research scientists. Mr. Lechner has also served as chief executive of numerous startup companies ranging from physician training products to computer system integration in China.

Mr. Norskog held numerous senior management positions for various divisions of Johnson & Johnson in North America and throughout Asia Pacific. His Asia experience includes serving as president of Xian-Janssen Pharmaceutical Ltd, a Johnson & Johnson joint venture with the Chinese Government, which was ranked among the top ten best ventures in China since 1991. Mr. Norskog also served as President of Johnson & Johnson China Development. Mr. Norskog's most recent engagement was as President of McNeil Consumer Healthcare, the division of Johnson & Johnson that markets Tylenol.

"We are pleased to have Mr. Lechner and Mr. Norskog join the Genyous Board of Directors. Their extensive commercial experience in managing new business development and industry expertise serves to bring additional breadth and depth to Genyous' Board," said James Dao, Chairman, President & CEO of Genyous Biomed.